Core Points - XOMA Royalty Corporation has extended its tender offer to purchase all outstanding shares of LAVA Therapeutics N.V. until October 17, 2025, with the acquisition expected to close in Q4 2025 [1][2] Group 1: Tender Offer Details - The tender offer includes a cash amount and a non-transferable contingent value right (CVR) per share, entitling shareholders to 75% of net proceeds from LAVA's partnered assets and any out-licensed or sold unpartnered programs [1] - LAVA shareholders who have already tendered their shares do not need to take further action due to the extension of the offer [3] - The closing of the offer is contingent upon the tender of at least 80% of LAVA's outstanding shares, adoption of certain resolutions by LAVA's shareholders, and other customary closing conditions [4] Group 2: Company Background - XOMA Royalty is a biotechnology royalty aggregator that acquires future economic rights associated with therapeutic candidates licensed to pharmaceutical companies, providing non-dilutive funding to sellers [5] - LAVA Therapeutics is a biopharmaceutical company focused on developing bispecific gamma delta T cell engagers using its proprietary Gammabody® platform, with partnerships with Johnson & Johnson and Pfizer [6][7]

Core Viewpoint - Moatable, Inc. has announced the preliminary results of its fixed price tender offer to repurchase up to 225 million Class A ordinary shares at a price of $3.00 per share, with a total expected acquisition of approximately 85 million shares for about $5.67 million [1][2]. Group 1: Tender Offer Details - The tender offer expired on September 30, 2025, and a total of 85,065,660 Class A ordinary shares were properly tendered [2]. - The shares to be acquired represent approximately 13.0% of the total outstanding Class A ordinary shares and about 10.3% of the company's outstanding share capital [2]. - The acquisition will be funded through cash on hand and a new $9.75 million senior secured credit facility with PNC Bank [1]. Group 2: Company Background - Moatable, Inc. operates two US-based SaaS businesses, Lofty and Trucker Path, and its American Depositary Shares trade on the Pink Limited Market under the symbol "MTBLY" [5].

Core Points - The tender offer was rejected by the company due to three main reasons: the offer significantly undervalues the potential of Sabadell, the company can create more value for shareholders on a stand-alone basis with a focus on capital distribution, and there are risks associated with BBVA shares that Sabadell shares do not have [1] Summary by Categories - **Valuation Concerns** - The offer is perceived to significantly undervalue the potential of Sabadell [1] - **Value Creation** - The company believes it can generate more value for shareholders independently, emphasizing capital distribution strategies [1] - **Risk Assessment** - The company highlighted that BBVA shares carry certain risks that are not present with Sabadell shares [1]

Group 1 - abrdn Japan Equity Fund, Inc. (NYSE: JEQ) is announcing details regarding its tender offer and the upcoming reorganization with abrdn Global Infrastructure Income Fund (NYSE: ASGI) [1] - The tender offer will expire on September 2, 2025, at 5:00 PM ET, with a valuation date of September 3, 2025, pricing shares at 98% of the NAV determined as of that date [9] - The settlement date for the tender offer is set for September 12, 2025, with a potential final distribution announcement on September 19, 2025, if necessary [9] Group 2 - The last day of trading for JEQ is anticipated to be on or about October 10, 2025, after which shareholders will receive newly issued common shares of ASGI equivalent to the aggregate net asset value of their JEQ shares [9] - Shareholders of JEQ as of market close on October 10, 2025, will be deemed shareholders of ASGI at the open of market trading hours on October 13, 2025 [9]

Core Viewpoint - Rocket Companies, Inc. is initiating tender offers to acquire outstanding senior notes from Nationstar Mortgage Holdings Inc. as part of its acquisition of Mr. Cooper Group Inc. [1][2] Tender Offers - The company is offering to purchase 5.125% Senior Notes due 2030 and 5.750% Senior Notes due 2031, with aggregate principal amounts of US$650 million and US$600 million respectively [3][4] - The tender offer consideration for both notes is set at $962.50 per $1,000 principal amount, with an early tender payment of $50, bringing the total tender offer consideration to $1,012.50 for early tenders [3][4] Consent Solicitations - The company is soliciting consents to amend the indentures governing the notes, which includes eliminating the "Change of Control" offer requirement and most restrictive covenants [2][9] - A majority of the aggregate principal amount of the notes must provide consent for the proposed amendments to be adopted [9] Timeline and Conditions - The tender offers and consent solicitations will expire on September 2, 2025, with an early tender deadline of August 15, 2025 [7][11] - The consummation of the tender offers is contingent upon receiving the requisite consents and the successful completion of the acquisition of Mr. Cooper [10]

Group 1 - Black Pearl Equities announced a tender offer to purchase up to 49.9% of the outstanding common shares of Regional Health Properties at a price of $4.25 per share in cash, expiring on August 31, 2025 [1] - The tender offer provides liquidity for shareholders and an alternative to holding their investment, allowing them to tender shares at a premium to recent market prices [2] - The offer is contingent upon obtaining valid tenders for a minimum of 45% of the outstanding shares and other specific conditions, including no material adverse changes to the company's financial or operational condition [3]

Core Viewpoint - Transom Capital Group has successfully completed a tender offer to acquire SigmaTron International, with 71.9% of shares validly tendered at a price of $3.02 per share, and the acquisition is expected to be finalized on July 28, 2025 [1][2][3] Group 1: Acquisition Details - The tender offer for SigmaTron shares expired on July 24, 2025, with a purchase price of $3.02 per share [1] - A total of 4,401,189 shares were validly tendered, representing 71.9% of the outstanding shares [2] - All conditions for the tender offer have been satisfied, and Transom will accept and pay for the validly tendered shares [2] Group 2: Company Background - Transom Capital Group is a private equity firm founded in 2008, specializing in operationally-focused investments in the middle market [5] - The firm has a strong track record in various economic cycles, focusing on corporate carve-outs and undervalued public companies [5][6] - SigmaTron operates as an independent provider of electronic manufacturing services, with facilities in the U.S., Mexico, China, and Vietnam [7] Group 3: Advisory Roles - Kirkland & Ellis LLP is serving as the legal advisor for Transom [4] - Lincoln International is the exclusive financial advisor for SigmaTron, with additional legal support from Greenberg Traurig, LLP and Howard & Howard Attorneys PLLC [4]

Core Viewpoint - Novartis has successfully completed a tender offer to acquire Regulus Therapeutics, with approximately 74.49% of the outstanding shares validly tendered [2] Group 1: Acquisition Details - Novartis offered $7.00 in cash per share plus one contingent value right (CVR) for each share, which represents a potential additional payment of $7.00 upon achieving a regulatory milestone [1] - The tender offer expired on June 24, 2025, at 11:59 p.m. New York City Time [1] - The transaction is expected to close on June 25, 2025, following the acceptance of all validly tendered shares [2] Group 2: Shareholder Participation - A total of approximately 56,374,397 shares were validly tendered, indicating strong shareholder support for the acquisition [2]

Core Viewpoint - Crown Electrokinetics Corp. has entered into a definitive Merger Agreement with Crown EK Acquisition LLC, which will lead to Crown becoming a wholly owned subsidiary of Parent, controlled by Douglas Croxall, the Company's Chairman and CEO [1][2][3]. Group 1: Merger Agreement Details - The Merger Agreement stipulates that Purchaser will initiate a tender offer to acquire all outstanding shares of Crown's common stock at a cash price of $3.15 per share [2]. - The transaction has received unanimous approval from a special committee of independent directors, who determined it to be fair to Crown's unaffiliated public stockholders [3]. - The tender offer is expected to commence within 15 business days and will remain open for 20 business days, unless extended [4]. Group 2: Transaction Structure and Timeline - The transaction is not subject to a financing condition and is anticipated to close promptly after the successful completion of the tender offer [4]. - Additional information regarding the transaction will be filed with the SEC and made available on Crown's investor relations website [5]. Group 3: Company Overview - Crown is recognized as a leading provider of innovative technology infrastructure solutions, operating across multiple sectors including Smart Windows and Construction [6].

Group 1 - The Company intends to consider the delisting of all outstanding shares from trading on the regulated market AB Nasdaq Vilnius at an extraordinary general meeting scheduled for 30 June 2025 [1] - Shareholders wishing to vote "for" the delisting decision are encouraged to submit their draft resolutions by 5 June 2025 [1] - A letter from shareholder AB "HISK" has been received regarding the provision of draft decisions for the upcoming meeting [1] Group 2 - The draft resolution proposes to initiate the delisting of all outstanding shares from trading on the regulated market AB Nasdaq Vilnius [2] - Article 33(7) of the Law of the Republic of Lithuania on Securities requires shareholders voting "for" the delisting to submit a tender offer, but the proposal allows AB "HISK" to submit the tender offer while other shareholders retain the right to sell their shares during the tender offer [3] - The decisions regarding delisting and the related tender offer are valid only if the tender offer price does not exceed the established price [3] Group 3 - The tender offer price for delisting will be set at EUR 0.735, which includes a 33% premium over the fair price of EUR 0.553 as per the relevant legal provisions [4] - The draft resolution authorizes the General Manager of the Company to take necessary actions and submit documents for the delisting process after the tender offer is implemented [5][6]